JP2025513502A5 - - Google Patents

Info

Publication number
JP2025513502A5
JP2025513502A5 JP2024562212A JP2024562212A JP2025513502A5 JP 2025513502 A5 JP2025513502 A5 JP 2025513502A5 JP 2024562212 A JP2024562212 A JP 2024562212A JP 2024562212 A JP2024562212 A JP 2024562212A JP 2025513502 A5 JP2025513502 A5 JP 2025513502A5
Authority
JP
Japan
Prior art keywords
approximately
aqueous composition
pharmaceutically acceptable
acceptable salt
rilpivirine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024562212A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025513502A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2023/060689 external-priority patent/WO2023203258A1/en
Publication of JP2025513502A publication Critical patent/JP2025513502A/ja
Publication of JP2025513502A5 publication Critical patent/JP2025513502A5/ja
Pending legal-status Critical Current

Links

JP2024562212A 2022-04-22 2023-04-24 液体組成物 Pending JP2025513502A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202263333556P 2022-04-22 2022-04-22
US63/333,556 2022-04-22
EP22173922 2022-05-17
EP22173922.0 2022-05-17
PCT/EP2023/060689 WO2023203258A1 (en) 2022-04-22 2023-04-24 Liquid compositions

Publications (2)

Publication Number Publication Date
JP2025513502A JP2025513502A (ja) 2025-04-24
JP2025513502A5 true JP2025513502A5 (cg-RX-API-DMAC7.html) 2026-05-08

Family

ID=86316741

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024562212A Pending JP2025513502A (ja) 2022-04-22 2023-04-24 液体組成物

Country Status (7)

Country Link
US (1) US20250268896A1 (cg-RX-API-DMAC7.html)
EP (1) EP4511003A1 (cg-RX-API-DMAC7.html)
JP (1) JP2025513502A (cg-RX-API-DMAC7.html)
CN (1) CN119403543A (cg-RX-API-DMAC7.html)
CA (1) CA3249515A1 (cg-RX-API-DMAC7.html)
TW (1) TW202408516A (cg-RX-API-DMAC7.html)
WO (1) WO2023203258A1 (cg-RX-API-DMAC7.html)

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3429B1 (ar) 2001-08-13 2019-10-20 Janssen Pharmaceutica Nv مشتقات برميدينات مثبطة فيروس الايدز
EP2330213A1 (en) 2003-03-05 2011-06-08 Halozyme, Inc. Soluble hyaluronidase glycoprotein (sHASEGP), process for preparing the same, uses and pharmaceutical compositions comprising thereof
PT3366278T (pt) 2006-06-23 2024-10-21 Janssen Sciences Ireland Unlimited Co Suspensões aquosas de tmc278
WO2009128917A2 (en) * 2008-04-14 2009-10-22 Halozyme, Inc. Modified hyaluronidases and uses in treating hyaluronan-associated diseases and conditions
AU2020344675B2 (en) * 2019-09-13 2026-06-25 Halozyme Hypercon, Inc. Compositions and methods for the delivery of therapeutic biologics for treatment of disease
WO2022109555A1 (en) 2020-11-17 2022-05-27 Janssen Sciences Ireland Unlimited Company Treatment or prevention of hiv infection

Similar Documents

Publication Publication Date Title
JP2017036306A (ja) 経口投与型コルチコステロイド組成物
JP2024156754A5 (cg-RX-API-DMAC7.html)
US20220304934A1 (en) Brivaracetam pharmaceutical composition, preparation method therefor and use thereof
US20080152712A1 (en) Rapidly disintegrating lyophilized oral formulations of a thrombin receptor antagonist
CN105338969A (zh) 具有改善的稳定性的包含左西替利嗪和孟鲁司特的复合颗粒制剂
US20240082195A1 (en) Compositions for treating fungal and bacterial biofilms and methods of using the same
JP6488003B2 (ja) 安定なモンテルカスト溶液
US20170258749A1 (en) Oseltamivir Compositions
KR20210158795A (ko) 나파모스타트 메실레이트를 유효성분으로 포함하는 경구용 약제학적 조성물
JP2005523329A5 (cg-RX-API-DMAC7.html)
KR102762379B1 (ko) 안과용 조성물
WO2004069280A1 (en) Pharmaceutical inclusion complexes containing a steroid and optionally an antibacterial agent
JP2006008684A (ja) ジクロフェナクナトリウムとβ−シクロデキストリンとを有する注入可能薬学組成物
EP3013316B1 (en) Stable intravenous formulation
JPH10502616A (ja) Dx−52−1化合物の安定化法及びその凍結乾燥組成物
JPH0249720A (ja) 難溶性薬剤組成物
CN116098864A (zh) 一种利那洛肽干混悬剂及其制备方法
JP2025513501A5 (cg-RX-API-DMAC7.html)
TWI918738B (zh) 布瓦西坦藥物組合物、其製備方法及應用
JP2001187735A (ja) 安定なニコランジル含有粉末の製造法
AU2021286284B2 (en) Antimicrobial compositions with effervescent agents
WO2014071743A1 (zh) 含有抗真菌药物和乳酸盐缓冲剂的组合物
ES2629103T3 (es) Formulación en polvo de valganciclovir
CZ286610B6 (cs) Intranasální kompozice proti migréně
JPH1180021A (ja) バンコマイシン注射剤